Abstract
Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.
| Original language | English |
|---|---|
| Pages (from-to) | 372-374 |
| Number of pages | 3 |
| Journal | British Journal of Dermatology |
| Volume | 156 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2007 |
Fingerprint
Keywords
- Ciclosporin
- Everolimus
- Psoriasis
ASJC Scopus subject areas
- Dermatology
Cite this
Severe psoriasis treated with a new macrolide : Everolimus. / Frigerio, E.; Colombo, M. D.; Franchi, C.; Altomare, A.; Garutti, C.; Altomare, G. F.
In: British Journal of Dermatology, Vol. 156, No. 2, 02.2007, p. 372-374.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Severe psoriasis treated with a new macrolide
T2 - Everolimus
AU - Frigerio, E.
AU - Colombo, M. D.
AU - Franchi, C.
AU - Altomare, A.
AU - Garutti, C.
AU - Altomare, G. F.
PY - 2007/2
Y1 - 2007/2
N2 - Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.
AB - Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.
KW - Ciclosporin
KW - Everolimus
KW - Psoriasis
UR - http://www.scopus.com/inward/record.url?scp=33846189774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846189774&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2133.2006.07602.x
DO - 10.1111/j.1365-2133.2006.07602.x
M3 - Article
C2 - 17223881
AN - SCOPUS:33846189774
VL - 156
SP - 372
EP - 374
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 2
ER -